Serotonin toxicity from antidepressant overdose and its association with the T102C polymorphism of the 5-HT 2A receptor

Pharmacogenomics Journal

Volumn 14, Issue 4, 2014, Pages 390-394

  Cooper, J M ^a   Newby, D A ^a   Whyte, I M ^a,b   Carter, G ^b   Jones, A L ^c   Isbister, G K ^a,b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

5HT2A; genotype; polymorphism; serotonin 2A receptor; serotonin syndrome; serotonin toxicity

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MOCLOBEMIDE; PAROXETINE; SEROTONIN 2A RECEPTOR; SEROTONIN AGONIST; SERTRALINE; VENLAFAXINE; ANTIDEPRESSANT AGENT; SEROTONIN;

5 HT2A GENE; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA POLYMORPHISM; DOSE RESPONSE; DRUG OVERDOSE; DRUG WITHDRAWAL; ETHNIC GROUP; EUROPEAN; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN CELL; INCIDENCE; INDIGENOUS AUSTRALIAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEPTOR GENE; SEROTONIN SYNDROME; UNSPECIFIED SIDE EFFECT; ADULT; COHORT ANALYSIS; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED;

ADULT; ANTIDEPRESSIVE AGENTS; COHORT STUDIES; DRUG OVERDOSE; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN;

EID: 84905059674     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2013.47     Document Type: Article

References (41)

1. Australia's Health. The Twelfth Biennial Report of the Australian Institute of Health and Welfare. AIHW: Canberra, Australia, 2010.
2. Health United States, 2012: with Special Feature on Emergency Care. National Center for Health Statistics: Hyattsville, MD, USA, 2013.
3. Australian Statistics on Medicines 2010. Australian Government Department of Health and Ageing: Canberra, Australia, 2012.
4. Wong DT, Bymaster FP, Horng JS, Molloy BB. A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy) . N-methyl-3-phenylpropylamine. J Pharmacol Exp Ther 1975; 193: 804-811.
5. Koek W, Vacher B, Cosi C, Assie MB, Patoiseau JF, Pauwels PJ et al. 5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential. Eur J Pharmacol 2001; 420: 103-112.
6. Maurel JL, Autin JM, Funes P, Newman-Tancredi A, Colpaert F, Vacher B. High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity. J Med Chem 2007; 50: 5024-5033.
7. Koek W, Patoiseau JF, Assie MB, Cosi C, Kleven MS, Dupont-Passelaigue E et al. F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential. J Pharmacol Exp Ther 1998; 287: 266-283.
8. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust 2007; 187: 361-365.
9. Murphy DL, Fox MA, Timpano KR, Moya PR, Ren-Patterson R, Andrews AM et al. How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. Neuropharmacology 2008; 55: 932-960.
10. Norton N, Owen MJ. HTR2A: association and expression studies in neuropsychiatric genetics. Ann Med 2005; 37: 121-129.
11. Minov C, Baghai TC, Schule C, Zwanzger P, Schwarz MJ, Zill P et al. Serotonin-2A-receptor and-transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett 2001; 303: 119-122.
12. Illi A, Setala-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N et al. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 2009; 20: 1125-1128.
13. Serretti A, Cusin C, Lorenzi C, Lattuada E, Lilli R, Smeraldi E. Serotonin-2A receptor gene is not associated with symptomatology of schizophrenia. Am J Med Genet 2000; 96: 84-87.
14. Massat I, Souery D, Lipp O, Blairy S, Papadimitriou G, Dikeos D et al. A European multicenter association study of HTR2A receptor polymorphism in bipolar affective disorder. Am J Med Genet 2000; 96: 136-140.
15. Vaquero-Lorenzo C, Baca-Garcia E, Diaz-Hernandez M, Perez-Rodriguez MM, Fernandez-Navarro P, Giner L et al. Association study of two polymorphisms of the serotonin-2A receptor gene and suicide attempts. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 645-649.
16. Ertugrul A, Kennedy JL, Masellis M, Basile VS, Jayathilake K, Meltzer HY. No association of the T102C polymorphism of the serotonin 2A receptor gene (HTR2A) with suicidality in schizophrenia. Schizophr Res 2004; 69: 301-305.
17. González-Castro TB, Tovilla-Zárate C, Juárez-Rojop I, Pool García S, Velázquez-Sánchez MP, Genis A et al. Association of the 5HTR2A gene with suicidal behavior: case-control study and updated meta-analysis. BMC Psychiatry 2013; 13: 25.
18. Bondy B, Kuznik J, Baghai T, Schule C, Zwanzger P, Minov C et al. Lack of association of serotonin-2A receptor gene polymorphism (T102C) with suicidal ideation and suicide. Am J Med Genet 2000; 96: 831-835.
19. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M et al. Pharmaco-genetic prediction of clozapine response. Lancet 2000; 355: 1615-1616.
20. Cusin C, Serretti A, Zanardi R, Lattuada E, Rossini D, Lilli R et al. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI anti-depressant activity. Int J Neuropsychopharmacol 2002; 5: 27-35.
21. Niitsu T, Fabbri C, Bentini F, Serretti A. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2013; 45: 183-194.
22. Lattanzi L, Danesi R, Lastella M, Mungai F, Di Paolo A, Tuccori M et al. Serotonin syndrome and the T102-C polymorphism of the 5-HT2A receptor: a case report. Bipolar Disord 2008; 10: 655-656.
23. Murphy Jr. GM, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004; 61: 1163-1169.
24. Murphy Jr. GM, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160: 1830-1835.
25. Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol 2005; 28: 205-214.
26. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-713.
27. Radomski JW, Dursun SM, Reveley MA, Kutcher SP. An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses 2000; 55: 218-224.
28. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003; 96: 635-642.
29. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2013. Oslo, Norway, 2012.
30. Nisijima K, Yoshino T, Yui K, Katoh S. Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res 2001; 890: 23-31.
31. Kato M, Fukuda T, Wakeno M, Fukuda K, Okugawa G, Ikenaga Y et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 2006; 53: 186-195.
32. Tanaka M, Kobayashi D, Murakami Y, Ozaki N, Suzuki T, Iwata N et al. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and parox-etine-induced nausea. Int J Neuropsychopharmacol 2008; 11: 261-267.
33. Penas-Lledo EM, Dorado P, Caceres MC, de la Rubia A, Llerena A. Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs. Clin Chem Lab Med 2007; 45: 835-838.
34. Tansey KE, Guipponi M, Perroud N, Bondolfi G, Domenici E, Evans D et al. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med 2012; 9: e1001326.
35. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004; 9: 879-889.
36. Suzuki Y, Sawamura K, Someya T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology 2006; 31: 825-831.
37. Roberts RL, Mulder RT, Joyce PR, Luty SE, Kennedy MA. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol 2004; 19: 17-23.
38. Sugai T, Suzuki Y, Sawamura K, Fukui N, Inoue Y, Someya T. The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J 2006; 6: 351-356.
39. Gerstenberg G, Aoshima T, Fukasawa T, Yoshida K, Takahashi H, Higuchi H et al. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology (Berl) 2003; 167: 443-448.
40. Database of Single Nuclear Polymorphisms (dbSNP). Bethesda, MD, USA: National Centre for Biotechnology Information, National Library of Medicine. dbSNP accession: rs6313, (dbSNP Build ID:37.5). Available from http://www. ncbi.nlm.nih.gov/SNP/.
41. Chan AN, Gunja N, Ryan CJ. A comparison of venlafaxine and SSRIs in deliberate self-poisoning. J Med Toxicol 2010; 6: 116-121.